Intellia Therapeutics, Inc. (NTLA) News
Filter NTLA News Items
NTLA News Results
|Loading, please wait...|
NTLA News Highlights
- For NTLA, its 30 day story count is now at 8.
- Over the past 22 days, the trend for NTLA's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- GENE, EDIT and VIVO are the most mentioned tickers in articles about NTLA.
Latest NTLA News From Around the Web
Below are the latest news stories about Intellia Therapeutics Inc that investors may wish to consider to help them evaluate NTLA as an investment opportunity.
Photo by elenabs/iStock via Getty Images Over the past several years, Intellia (NTLA) has been developing the most advanced CRISPR in vivo platform in the industry. While CRISPR Therapeutics (CRSP) has captured the market’s attention with their industry leading treatment for sickle cell and beta-thalassemia (CTX-001), Intellia has presented by...
Intellia Therapeutics (NASDAQ: NTLA), Beam Therapeutics (NASDAQ: BEAM), and Twist Bioscience (NASDAQ: TWST) are all carving niches for themselves in that industry, adding to what we know about the human genome and using that knowledge in an attempt to fight some of the most stubborn diseases. Genetic medicine is a broad field, but ultimately it comes down to a relatively simple premise.
One that got my attention today is Intellia Therapeutics . The On-Balance-Volume (OBV) declined modestly into early March as prices corrected but the line has been rising again and tells us that buyers are once again being more aggressive. The OBV line is showing improvement from February and the MACD oscillator is crossing to the upside for a fresh outright buy signal.
Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting
- Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD) CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced the presentation of new data from its CRISPR/Cas9 platform at the 24th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place virtually from May 11-14, 2021. “The data accepted for presentation at ASGCT reflects our ongoing commitment to finding new ways to treat and potentially cure a variety of diseases. Utilizing our modular in vivo insertion technology, we demonstrate the potential to durably restore normal AAT protein levels after a single dose. We continue to advance multiple genome editing strategies for patien...
So what did the stock market do today?
A "sell" rating is one thing, but a price target barely half of the Thursday close?
The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing.
Leerink Partners Stick to Their Buy Rating for Intellia Therapeutics
Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present the first preclinical data set on its novel cytosine deaminase base editor technology at the seventh Cold Spring Harbor Laboratory (CSHL) virtual scientific meeting on Nucleic Acid Therapies. The data shows how the Company’s proprietary base editors can expand its genome editing capabilities by enabling the introduction of multiple gene knockouts simultaneously with no detectable increase in translocation above background levels. The meeting is being held virtually from March 24-26, 2021. “At Intellia, we continue to build the broadest and deepest genome editing platform for developing potentially curative treatments for severe diseases,” said Intellia President and Chief Executiv...
While stock picking isn't easy, for those willing to persist and learn, it is possible to buy shares in great...